In May 2026, Guardant Health announced FDA approval of Guardant360 Liquid CDx, describing it as a blood-based comprehensive genomic profiling test that integrates genomic and epigenomic insights for clinicians treating advanced cancer. The company said the approved panel assesses a substantially wider genomic footprint than its prior Guardant360 CDx and carries over previously approved companion diagnostic indications, with reported turnaround as fast as seven days in some settings.
This sits at the intersection of diagnostics, precision oncology, and hospital/lab commercial models—not traditional implantable device selling. Still, many “medical sales” job seekers encounter oncology diagnostics roles alongside device postings.
How Diagnostics Selling Differs from Device OR Roles
- Stakeholders include pathology, oncology, lab directors, and payer policy—not only surgeons
- Companion diagnostic language must stay precise; off-label promotion risk is real
- Evidence and coverage stories matter as much as relationship selling
- Turnaround time and sample logistics affect account stickiness
Career Guidance
Candidates should clarify whether a role is field-based lab service, oncology account management, or hospital contracting. Interview answers that only discuss OR cases may miss what hiring managers want in diagnostics. Employers should tag roles accurately—oncology diagnostics is not spine, and mismatched hires create compliance and ramp problems.